Program
camlipixant
Also written as “BLU-5937”, “Camlipixant” and “BLU-5937 ER”.
In GlaxoSmithKline’s pipeline, P2X3 receptor antagonist
. Its studies are mostly in Cough · Chronic Cough · Irritable Bowel Syndrome · Dermatitis, Atopic, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 161 open or running | phase 3since Oct 18, 2022 | Aug 15, 2018 | Mar 9, 2027phase 2 · NCT07519395 |
- Named in GlaxoSmithKline’s own pipeline as
camlipixant GSK5464714
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Aug 15, 2018.
- Dec 9, 20202 phase 2 studiesNCT04678206, NCT04693195
- Feb 11, 2022Phase 1 study in HealthyNCT05244759 · 6 enrolled · United Kingdom
- Jul 21, 2022Named camlipixantINNProposed as its International Nonproprietary Name in WHO's List 127 · before, BLU-5937
- Oct 3, 2022Phase 1 study in CoughNCT05570539 · 30 enrolled · United Kingdom
- Oct 18, 20222 phase 3 studies in CoughNCT05600777, NCT05599191
- Jun 2, 2023Phase 1 study in CoughNCT05899829 · 42 enrolled · Canada
- Jul 17, 2023Phase 1 study in CoughNCT05959447 · 45 enrolled · Canada
- Nov 27, 2023Phase 1 study in HealthyNCT06179537 · 34 enrolled · United Kingdom
- Jan 16, 2024Phase 1 study in CoughNCT06222892 · 32 enrolled · United States
- Jul 5, 2024Phase 1 study in CoughNCT06497517 · 14 enrolled · United States
- Apr 2, 2026Phase 2 study in Irritable Bowel SyndromeNCT07519395 · 420 planned · United States
- Jun 10, 2026Phase 3 study in Chronic CoughNCT07650084 · 75 enrolled · China
- Jun 29, 2026Phase 1 study in CoughNCT07684586 · United Kingdom
- Nov 20, 2026Phase 3 study terminatedStudy stoppedNCT05600777 · “The study has been terminated due to the decision to cease further development of camlipixant in refractory chronic cough (RCC), based on…”
- Nov 20, 2026Phase 3 study terminatedStudy stoppedNCT07650084 · “The study has been withdrawn terminated due to the decision to cease further development of camlipixant in refractory chronic cough (RCC)…”
Ahead
- Mar 9, 2027Primary completion: phase 2 study in Irritable Bowel SyndromeNCT07519395
TargetBeta
“P2X3 receptor antagonist”the company's pipeline, read by Claude · source
“P2X purinoceptor 3 antagonist”ChEMBL 37, by rule
Other programs on P2RX3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TCR1672 | Sino Biopharmaceutical | phase 2 | 1 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07684586Cough · United Kingdom | 1 | Withdrawn | Aug 27, 2027 | 0 |
| NCT07650084Chronic Cough · China | 3 | Terminated | Jul 17, 2026 | 75 |
| NCT07519395Irritable Bowel Syndrome · United States | 2 | Recruiting | Mar 9, 2027 | 420 |
| NCT06497517Cough · United States | 1 | Completed | Aug 22, 2024 | 14 |
| NCT06222892Cough · United States | 1 | Completed | Dec 17, 2024 | 32 |
| NCT06179537Healthy · United Kingdom | 1 | Completed | Oct 22, 2021 | 34 |
| NCT05959447Cough · Canada | 1 | Completed | Oct 13, 2023 | 45 |
| NCT05899829Cough · Canada | 1 | Completed | Aug 8, 2023 | 42 |
| NCT05600777Cough · United States, Australia, Canada and more | 3 | Terminated | Jun 10, 2026 | 1,019 |
| NCT05599191Cough · United States, Argentina, Belgium and more | 3 | Completed | Dec 17, 2025 | 957 |
| NCT05570539Cough · United Kingdom | 1 | Completed | May 2, 2024 | 30 |
| NCT05244759Healthy · United Kingdom | 1 | Completed | Sep 23, 2020 | 6 |
| NCT04693195Dermatitis, Atopic · United States, Canada | 2 | Completed | Oct 4, 2021 | 142 |
| NCT04678206Chronic Cough · United States, Canada, Czechia and more | 2 | Completed | Oct 21, 2021 | 310 |
| NCT03979638Chronic Cough · United States, United Kingdom | 2 | Terminated | Apr 23, 2020 | 68 |
| NCT03638180Cough · Canada | 1 | Completed | Oct 25, 2018 | 90 |
How it is read
Names in the registry
- “BLU-5937”, 8 entries
- “Camlipixant”, 5 entries
- “BLU-5937 ER”, 1 entry
- “GSK5464714- Camlipixant”, 1 entry
- “[14C]-BLU-5937”, 1 entry
Conditions, from the studies’ own filings
- Cough, 7 studies
- Chronic Cough, 5 studies
- Irritable Bowel Syndrome, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.